The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

ABSTRACT Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer's disease (AD). This paper describes the recruitment of the cohort and gives information about the study methodology, baseline demography, diagnoses, medical comorbidities, medication use, and cognitive function of the participants. Methods: Volunteers underwent a screening interview, had comprehensive cognitive testing, gave 80 ml of blood, and completed health and lifestyle questionnaires. One quarter of the sample also underwent amyloid PET brain imaging with Pittsburgh compound B (PiB PET) and MRI brain imaging, and a subgroup of 10% had ActiGraph activity monitoring and body composition scanning. Results: A total of 1166 volunteers were recruited, 54 of whom were excluded from further study due to comorbid disorders which could affect cognition or because of withdrawal of consent. Participants with AD (211) had neuropsychological profiles which were consistent with AD, and were more impaired than participants with mild cognitive impairment (133) or healthy controls (768), who performed within expected norms for age on neuropsychological testing. PiB PET scans were performed on 287 participants, 100 had DEXA scans and 91 participated in ActiGraph monitoring. Conclusion: The participants comprising the AIBL cohort represent a group of highly motivated and well-characterized individuals who represent a unique resource for the study of AD. They will be reassessed at 18-month intervals in order to determine the predictive utility of various biomarkers, cognitive parameters and lifestyle factors as indicators of AD, and as predictors of future cognitive decline.

[1]  R. Snaith,et al.  Doctors and overpopulation , 1986 .

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[3]  B. Reisberg,et al.  Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease , 2008, International Psychogeriatrics.

[4]  R. Martins,et al.  ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome , 1995, Neuroreport.

[5]  G. Grossberg,et al.  The Evolution of Psychiatric Symptoms in Alzheimer's Disease: A Natural History Study , 1996, Journal of the American Geriatrics Society.

[6]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[7]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[8]  E. Reiman,et al.  Vascular risk factors, incidence of MCI, and rates of progression to dementia , 2004, Neurology.

[9]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[10]  B. Reisberg.  Global measures: utility in defining and measuring treatment response in dementia , 2007, International Psychogeriatrics.

[11]  C. Jonker,et al.  Are memory complaints predictive for dementia? A review of clinical and population‐based studies , 2000, International journal of geriatric psychiatry.

[12]  G Ratcliff,et al.  Normative Data on the Boston Naming Test and Two Equivalent 30-Item Short Forms , 2000, The Clinical neuropsychologist.

[13]  J. Foster,et al.  Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. , 2008, JAMA.

[14]  T. L. Brink,et al.  Screening tests for geriatric depression , 1982 .

[15]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.

[16]  Amanda J. Patterson,et al.  The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle‐aged women in a study of iron supplementation , 2000, Australian and New Zealand journal of public health.

[17]  A K Anderson,et al.  Contribution of the anteromedial temporal lobes to the evaluation of facial emotion. , 2000, Neuropsychology.

[18]  T. Kudo,et al.  Biological markers as outcome measures for Alzheimer's disease interventions – real problems and future possibilities , 2007, International Psychogeriatrics.

[19]  H. Amièva,et al.  Incidence and outcome of mild cognitive impairment in a population-based prospective cohort , 2002, Neurology.

[20]  R. Dean,et al.  TEST REVIEW: Dean C. Delis, Edith Kaplan & Joel H. Kramer, Delis Kaplan Executive Function System (D-KEFS), The Psychological Corporation, San Antonio, TX, 2001. $415.00 (complete kit) , 2006 .

[21]  R. Corbo,et al.  Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? , 1999, Annals of human genetics.

[22]  W R Markesbery,et al.  Risk factors for transitions from normal to mild cognitive impairment and dementia , 2006, Neurology.

[23]  Jeffrey L. Cummings,et al.  The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.

[24]  HighWire Press.  Philosophical Transactions of the Royal Society of London , 1781, The London Medical Journal.

[25]  Mony J. de Leon,et al.  Subjective Memory Complaints: Presence, Severity and Future Outcome in Normal Older Subjects , 2007, Dementia and Geriatric Cognitive Disorders.

[26]  B. Ainsworth,et al.  International physical activity questionnaire: 12-country reliability and validity. , 2003, Medicine and science in sports and exercise.

[27]  C. Lyketsos,et al.  Depression in Alzheimer’s disease: overview and treatment , 2002, Biological Psychiatry.

[28]  O. Spreen,et al.  Comprar A Compendium of Neuropsychological Tests - Administration, Norms, and Commentary | Esther Strauss | 9780195159578 | Oxford University Press , 2009 .

[29]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[30]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[31]  M. Corballis.  The evolution and genetics of cerebral asymmetry , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[32]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[33]  D. Wechsler.  A Standardized Memory Scale for Clinical Use , 1945 .

[34]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[35]  Anthony F Jorm,et al.  The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms , 1989, Psychological Medicine.

[36]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[37]  M. Trabucchi,et al.  Patterns of antidepressants prescriptions in a large Italian old population , 2008, International journal of geriatric psychiatry.

[38]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[39]  O. Spreen,et al.  A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary , 1991 .

[40]  T. L. Brink,et al.  Clinical Gerontology: A Guide to Assessment and Intervention , 1986 .